Stay updated on XMT-1536 First-in-Human Study in NaPi2b-Expressing Cancers Clinical Trial
Sign up to get notified when there's something new on the XMT-1536 First-in-Human Study in NaPi2b-Expressing Cancers Clinical Trial page.

Latest updates to the XMT-1536 First-in-Human Study in NaPi2b-Expressing Cancers Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has been updated to reflect a new version of the study on XMT-1536, specifically focusing on the open-label, dose escalation model for patients with platinum-resistant ovarian cancer and non-squamous NSCLC. Key details about the study's structure and patient cohorts have been revised.SummaryDifference36%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check88 days agoChange DetectedThe page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to XMT-1536 First-in-Human Study in NaPi2b-Expressing Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XMT-1536 First-in-Human Study in NaPi2b-Expressing Cancers Clinical Trial page.